# NOV-002 in Myelodysplastic Syndrome (MDS)

> **NCT00960726** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** NOV-002

## Key facts

- **NCT ID:** NCT00960726
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn at sponsor request.
- **Last updated:** 2012-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960726, "NOV-002 in Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00960726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*